JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.02B |
| 2 |
iShares US Treasury Bond ETF
GOVT
|
+$3.55B |
| 3 |
Eli Lilly
LLY
|
+$2.61B |
| 4 |
Amphenol
APH
|
+$2.33B |
| 5 |
TotalEnergies
TTE
|
+$1.67B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$9.67B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$7.48B |
| 3 |
Meta Platforms (Facebook)
META
|
+$7.25B |
| 4 |
NVIDIA
NVDA
|
+$6.05B |
| 5 |
Microsoft
MSFT
|
+$5.54B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.15% |
| 2 | Miscellaneous | 24.97% |
| 3 | Financials | 9.75% |
| 4 | Consumer Discretionary | 8.78% |
| 5 | Healthcare | 7.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3476
Edgewise Therapeutics
EWTX
$4.5B
| $3.62M | ﹤0.01% |
146,038
+77,318
| +113% | +$1.55M |
2021 Q2
18 quarters
|
|
3477
iShares US Energy ETF
IYE
$1.69B
| $3.61M | ﹤0.01% |
75,990
-3,161
| -4% | -$150K |
2013 Q2
50 quarters
|
|
3478
QuidelOrtho
QDEL
$739M
| $3.61M | ﹤0.01% |
126,404
+903
| +0.7% | +$24.5K |
2015 Q3
41 quarters
|
|
3479
QuinStreet
QNST
$857M
| $3.6M | ﹤0.01% |
250,782
-154,270
| -38% | -$2.23M |
2016 Q3
37 quarters
|
|
3480
Relay Therapeutics
RLAY
$4.15B
| $3.6M | ﹤0.01% |
425,958
-36,421
| -8% | -$260K |
2020 Q3
21 quarters
|
|
|
BLDP
3481
Ballard Power Systems
BLDP
$720M
| $3.6M | ﹤0.01% |
1,418,389
+726,188
| +105% | +$2.25M |
2015 Q4
40 quarters
|
|
3482
Pebblebrook Hotel Trust 6.3% Series F Preferred Shares
PEB.PRF
$116M
| $3.6M | ﹤0.01% |
189,025
| – | – |
2025 Q1
3 quarters
|
|
3483
Orthofix Medical
OFIX
$370M
| $3.6M | ﹤0.01% |
237,273
-20,762
| -8% | -$317K |
2015 Q2
42 quarters
|
|
3484
Dentsply Sirona
XRAY
$1.73B
| $3.59M | ﹤0.01% |
313,789
-103,067
| -25% | -$1.21M |
2013 Q2
50 quarters
|
|
3485
Sally Beauty Holdings
SBH
$1.52B
| $3.59M | ﹤0.01% |
251,423
+172,320
| +218% | +$2.6M |
2015 Q4
40 quarters
|
|
3486
Goldman Sachs Access Treasury 0-1 Year ETF
GBIL
$7.89B
| $3.58M | ﹤0.01% |
35,813
-47,902
| -57% | -$4.79M |
2023 Q2
10 quarters
|
|
3487
Capitol Federal Financial
CFFN
$1.06B
| $3.57M | ﹤0.01% |
524,447
-63,987
| -11% | -$416K |
2013 Q2
50 quarters
|
|
|
ESPR
3488
DELISTED
Esperion Therapeutics
ESPR
| $3.57M | ﹤0.01% |
965,059
+19,568
| +2% | +$63.2K |
2015 Q3
41 quarters
|
|
3489
CALL
Moderna
MRNA
$75.9B
| $3.57M | ﹤0.01% |
121,000
+120,800
| +60,400% | +$3.28M |
2024 Q2
6 quarters
|
|
|
GLIBK
3490
Liberty Capital Corp Series C GCI Group Common Stock
GLIBK
$927M
| $3.56M | ﹤0.01% |
95,645
+45,054
| +89% | +$1.58M |
2025 Q3
1 quarter
|
|
3491
Equinox Gold
EQX
$13B
| $3.56M | ﹤0.01% |
253,243
-277,966
| -52% | -$3.51M |
2024 Q3
5 quarters
|
|
3492
American Superconductor
AMSC
$1.45B
| $3.54M | ﹤0.01% |
123,103
+8,215
| +7% | +$355K |
2024 Q1
7 quarters
|
|
3493
Kimco Realty Corp 7.25% Class N Preferred Stock
KIM.PRN
| $3.54M | ﹤0.01% |
60,430
| – | – |
2024 Q1
7 quarters
|
|
|
BSCY
3494
Invesco BulletShares 2034 Corporate Bond ETF
BSCY
$591M
| $3.53M | ﹤0.01% |
168,164
+76,212
| +83% | +$1.61M |
2025 Q3
1 quarter
|
|
3495
GeneDx Holdings
WGS
$2.18B
| $3.53M | ﹤0.01% |
27,148
-646
| -2% | -$88.7K |
2021 Q4
16 quarters
|
|
|
CTLP
3496
DELISTED
Cantaloupe
CTLP
| $3.53M | ﹤0.01% |
332,372
+159,631
| +92% | +$1.69M |
2020 Q4
20 quarters
|
|
3497
Vanguard Russell 2000 Value ETF
VTWV
$1.32B
| $3.53M | ﹤0.01% |
22,069
-1,647
| -7% | -$261K |
2020 Q2
22 quarters
|
|
3498
Sprott Physical Silver Trust
PSLV
$12.4B
| $3.53M | ﹤0.01% |
149,220
+3,230
| +2% | +$59.2K |
2021 Q1
19 quarters
|
|
3499
CALL
BILL Holdings
BILL
$3.72B
| $3.53M | ﹤0.01% |
64,700
+29,700
| +85% | +$1.53M |
2024 Q4
4 quarters
|
|
3500
Burke & Herbert Financial Services Corp
BHRB
$1.41B
| $3.52M | ﹤0.01% |
56,434
+1,250
| +2% | +$78.4K |
2023 Q2
10 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2025 Portfolio in Review
As of Q4 2025, JP Morgan Chase held 7,944 positions worth $1.59T, down 4.6% from $1.67T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
JP Morgan Chase withdrew a net $106B in Q4 2025, closing 563 positions and reducing 3,329 holdings. Its most notable exit was Interpublic Group of Companies, an estimated $228M position sold in full.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, JP Morgan Chase opened a new position in Quadratic Interest Rate Volatility and Inflation Hedge ETF worth $99.9M.
- JP Morgan Chase's largest Q4 2025 buy was Quadratic Interest Rate Volatility and Inflation Hedge ETF: 5,216,227 shares worth $99.9M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q4 2025, an estimated $4.02B increase.
- JP Morgan Chase's biggest Q4 2025 reduction was Vanguard S&P 500 ETF, cutting an estimated $9.67B.
- JP Morgan Chase fully exited Interpublic Group of Companies in Q4 2025, selling an estimated $228M.
- JP Morgan Chase's ten largest holdings make up 26% of its $1.59T portfolio in Q4 2025.
- JP Morgan Chase opened 577 new positions and closed 563 in Q4 2025.
- JP Morgan Chase's portfolio value fell 4.6% quarter-over-quarter to $1.59T.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.